Protein

Description
The protein product comprises a ubiquitin-like protein, FUBI, with ribosomal protein S30 as a carboxyterminal extension protein (CEP); other ribosomal proteins are produced as CEPs fused to ubiquitin. FUBI and S30 are thought to be cleaved post-translationally, but the enzyme catalyzing this step has not been identified. Whilst FUBI shows a high degree of sequence similarity to ubiquitin, notably retaining the C-terminal G-G dipeptide motif that is required for isopeptide bond formation between ubiquitin and lysines of target proteins, it lacks internal lysine residues (especially lysine-48) which serve as sites of polyubiquitin chain formation and usually facilitate proteasomal degradation of target molecules. Rather, modification of proteins with monomers of ubiquitin or ubiquitin-like proteins may influence the activity, intracellular localisation or inter-molecular interactions of target proteins. Little information exists regarding target proteins for FUBI in human cells. In mouse, four target proteins have been identified. Covalent modification occurs for: (i) a T-cell receptor alpha-like protein (resulting in the production of murine monoclonal non-specific suppressor factor, which exhibits immunomodulatory activity); (ii) Bcl-G (a proapoptotic member of the Bcl-2 family; and (iii) endophilin II (regulates phagocytosis in mouse macrophages). Non-covalent modification of histone 2A has also been reported.
Expression
Steady state FAU mRNA levels are highly abundant and largely invariant in normal tissues indicative of a house-keeping gene role. However, physiological variations occur in FAU expression, notably in endometrium. FAU transcript levels have been reported to be reduced in a number of human cancers, including those affecting the breast, the prostate and the ovary.
Localisation
Cytosolic, ribosomal and nuclear localisations have been reported for FAU products. In addition, secretion of FUBI (in association with a T-cell receptor-alphalike molecule) has been reported for some immune system cell types.
Function
FAU regulates apoptosis in human epithelial and T-cell lines. It also possesses immunomodulatory and antimicrobial activities, and encodes a constituent of the ribosome. Regulation of apoptosis Functional expression cloning in mouse leukemic cell lines, with selection (dexamethasone and gammairradiation) for suppression of cell death, led to the isolation of a sequence which was antisense to FAU (Mourtada-Maarabouni et al., 2004) . Subcloning experiments confirmed that this antisense sequence produced resistance to apoptosis induced by dexamethasone and, additionally, by cisplatin and by ultraviolet-C irradiation. The antisense sequence reduced endogenous FAU expression. Conversely, overexpression of FAU promoted cell death, and this effect could be prevented by co-transfection with a plasmid encoding Bcl-2 (an anti-apoptotic factor) or by inhibition of caspases. Further work in human T-cell lines and the epithelial cell line, 293T/17, has confirmed that ectopic FAU expression increases basal apoptosis, and that siRNA-mediated silencing of FAU attenuates apoptosis in response to ultraviolet-C irradiation (Pickard et al., 2011) . FAU also regulates apoptosis in other human epithelial cell lines derived from breast (Pickard et al., 2009) , ovarian (Moss et al., 2010) and prostate tumours (see 'Implicated in'). FUBI has been shown to covalently modify Bcl-G (a pro-apoptotic member of the Bcl-2 family) in mouse cells (Nakamura and Tanigawa, 2003) , and it is feasible therefore, that FAU regulates apoptosis via Bcl-G. Indeed, prior knockdown of Bcl-G ablated the stimulation of basal apoptosis by FAU in human cells (Pickard et al., 2011) . This pro-apoptotic activity may underlie the putative tumour suppressor role of FAU, since failure of apoptosis is known to play a central role in the development of many cancers. Immunomodulation Monoclonal non-specific suppressor factor (MNSF) was first isolated from mouse cells in 1986 (Nakamura et al., 1988) and subsequently, from ascites fluid of a patient with systemic lupus erythematosus ; most studies of MNSF to-date have focussed on murine cells. This lymphokine-like molecule, which comprises alpha-and beta-chains, is secreted by CD8+ T-cells . cDNA encoding MNSFbeta was first isolated from the mouse in 1995, and it was shown to be identical to FAU . MNSF inhibits, inter alia, proliferation of mitogen-stimulated T-and B-cells, immunoglobulin secretion by B-cells in an isotype-specific manner (IgE and IgG3 are especially affected), TNFalpha production by activated macrophages and interleukin-4 secretion by bone marrow-derived mast cells and by a type-2 helper T-cell clone (Nakamura et al., 1988; Nakamura et al., 1994; Xavier et al., 1994; Xavier et al., 1995; Suzuki et al., 1996) . Inhibitory effects on T-and B-cell proliferation are subject to negative regulation by interleukin-2 (Nakamura et al., 1988) . Many of these immunosuppresive effects of MNSF can be ascribed to the MNSFbeta subunit, and specifically to FUBI (aka Ubi-L) . Cell surface receptors for MNSF have been described in target cells (Nakamura et al., 1992) , and these exhibit similarities to cytokine receptors , with tyrosine phosphorylation being implicated in transmembrane signalling (Nakamura and Tanigawa, 2000; Nakamura et al., 2002) . Both the expression of cell surface receptors on target cells and the secretion of MNSFbeta/FUBI by splenocytes are stimulated by interferon-gamma (Nakamura et al., 1992; . In splenocytes, FUBI conjugates to a range of intracellular proteins, including a T-cell receptoralpha-like molecule; the resulting complex, which comprises intact MNSF, is secreted by cells Nakamura et al., 2002) . FUBI also covalently modifies Bcl-G in spleen but not in testis, despite high levels of Bcl-G expression in the latter tissue (Nakamura and Tanigawa, 2003) . In macrophages, the FUBI/Bcl-G adduct binds to ERKs and inhibits ERK activation by MEK1 (Nakamura and Yamaguchi, 2006) . In liver and macrophages, FUBI also forms an adduct with endophilin II and inhibits phagocytosis by macrophages (Nakamura and Shimosaki, 2009; Nakamura and Watanabe, 2010) . Host defence An anti-microbial protein, termed ubiquicidin, has been isolated from the cytosol of a mouse macrophage cell line treated with interferon-gamma; the protein is active against Listeria monocytogenes, Salmonella typhimurium, Escherichia coli, Staphylococcus aureus and Yersinia enterocolitica (Hiemstra et al., 1999) . Ubiquicidin is identical to FAU-encoded ribosomal protein S30 (Hiemstra et al., 1999) . Ubiquicidin is also produced by human colonic mucosa (Tollin et al., 2003) and rainbow trout skin (Fernandes and Smith, 2002) . It is also active against methicillin-resistant Staphylococcus aureus and accumulates at sites of infection in mice (Brouwer et al., 2006) . Radiolabelled ubiquicidin has applications in clinical imaging for microbial infections (Brouwer et al., 2008) .
Homology
At the amino acid level, FUBI has 37/57% sequence identity/similarity to ubiquitin.
Implicated in
Various cancers
Note Tumor suppression: The retrovirus, FBR-MuSV, which contains the transduced genes v-fos and fox, can induce osteosarcomas in mice. In vitro experiments have shown that fox increases the transforming capacity of FBR-MuSV approximately two-fold . Fox is an antisense sequence to the cellular gene FAU, indicative of a tumour suppressor role for FAU. Retropseudogenes of FAU have been identified in human (Kas et al., 1995) and mouse (Casteels et al., 1995) genomes, suggesting a possible source for the viral fox gene (which is antisense to FAU). Further evidence for a tumour suppressor role for FAU has come from studies of the human carcinogen arsenite. Thus, functional cloning approaches in Chinese hamster V79 cells with selection for arsenite resistance, resulted in the isolation of the asr1 gene, which is homologous to FAU (Rossman and Wang, 1999) . Subsequent work by this group using human osteogenic sarcoma cells, indicated that the ability to confer arsenite resistance resided in the S30 domain of FAU (Rossman et al., 2003) . Oncogenesis Expression of the FUBI domain of FAU has been shown to transform human osteogenic sarcoma cells to anchorage-independent growth (Rossman et al., 2003) .
Breast cancer
Note Serial analysis of gene expression (SAGE) identified FAU as an underexpressed gene in ductal carcinoma in situ when compared with normal breast epithelium (Abba et al., 2004) . This was subsequently confirmed using quantitative RT-PCR analysis of matched (same patient) samples of breast cancer tissue and adjacent breast epithelial tissue (Pickard et al., 2009) . Furthermore, in a separate group of breast cancer patients, expression levels of FAU (determined by cDNA microarray analysis) were shown to be related to patient survival in Kaplan-Meier analyses (Pickard et al., 2009 ). This analysis indicated that higher expression of Fau has a protective effect, consistent with its candidate tumour suppressor role. Whilst Bcl-G expression was also shown to be down-regulated in breast cancer, Bcl-G expression was not related to patient survival (Pickard et al., 2009) , suggesting that the regulation of Bcl-G activity by post-translational modification is more important than Bcl-G expression per se in determining breast cancer patient survival. Functional studies in the T-47D breast cancer cell line demonstrated that down-regulation of either FAU or Bcl-G expression by siRNA-mediated silencing attenuated apoptosis induction by ultraviolet-C irradiation (Pickard et al., 2009) . Notably, no additional effect was observed when the two genes were simultaneously silenced, consistent with a role for Bcl-G in mediating the pro-apoptotic activity of FAU.
Ovarian cancer
Note A reduction in FAU gene expression has been reported for malignant versus normal ovarian tissue, and for Type I ovarian tumours (typically include mucinous, endometrioid, clear cell, and low-grade serous cancers), in particular (Moss et al., 2010) . Over-expression of FAU in a cisplatin-resistant ovarian cancer cell subline, A2780cis, resulted in increased sensitivity to carboplatin-induced apoptosis (Moss et al., 2010) . Conversely, down-regulation of FAU in the A2780 parental cell line resulted in increased resistance to carboplatin-induced apoptosis (Moss et al., 2010) . These in vitro findings suggest a role for FAU in the regulation of platinum-based drug resistance in ovarian cancer.
Prostate cancer
Note Steady state FAU mRNA levels are down-regulated in prostate cancer when compared with normal tissue and tissue from patients with benign prostate hyperplasia; a similar trend was found for Bcl-G . siRNA-mediated silencing of FAU or Bcl-G expression in the prostate cell line, 22Rv1, attenuated apoptosis induction consequent upon ultraviolet-C irradiation. A similar degree of apoptosis resistance was observed when the two genes were simultaneously down-regulated, consistent with FAU and Bcl-G acting in the same pathway.
Reproduction (implantation)
Note FAU is expressed in endometrial stromal cells in nonpregnant mouse uterus (Salamonsen et al., 2002) and it is also expressed in human endometrium (Nie et al., 2005) . In the mouse uterus, differential expression of FAU occurs during blastocyst implantation, with low expression levels noted in implantation versus interimplantation sites (Nie et al., 2000) . Expression levels remain low as implantation advances (Nie et al., 2000) . Administration of antisera to FAU into the mouse uterine lumen inhibits implantation in a dosedependent manner (Wang et al., 2007) , suggesting an essential role for secreted products in implantation. Trophoblast-derived interferons have been shown to induce endometrial FAU expression in pigs (Chwetzoff and d'Andrea, 1997) , also supporting an important role for FAU in early pregnancy.
Breakpoints
Note A t(11;14)(q13;q21)-positive B-cell non-Hodgkin's lymphoma patient has been described with an additional translocation of t(11;17)(q13;q21). The chromosome 11 breakpoint in the latter translocation was reported as a 40 kbp region around FAU.
